KALV Insider Activity: 4,203 RSU Shares Vest; 2,649 Sold to Cover Taxes
Rhea-AI Filing Summary
Christopher Yea, Chief Development Officer and director of KalVista Pharmaceuticals (KALV), reported the vesting/settlement of equity awards on 08/17/2025 that resulted in the acquisition of 4,203 shares of common stock, bringing his beneficial ownership to 132,142 shares. A subsequent transaction on 08/18/2025 shows a sale of 2,649 shares at $13.187 per share to satisfy tax withholding obligations related to the vesting. The filing discloses two restricted stock unit grant schedules with periodic vesting: one vesting 1/16th quarterly from August 17, 2022, and another vesting 1/12th quarterly from November 17, 2022. The RSUs/PSUs are contingent rights to receive one share each upon settlement for no consideration.
Positive
- Vesting of equity awards increased insider ownership by 4,203 shares, demonstrating continued alignment with company performance incentives
- Substantial remaining beneficial ownership of 132,142 shares after the transactions
Negative
- Sale of 2,649 shares reduced the insider's holdings; however, the filing states it was a sell-to-cover for tax withholding
- No discretionary open-market purchases were reported that would indicate additional insider buying interest
Insights
TL;DR Insider received vested awards and sold a small portion to cover taxes; overall holding remains sizable.
The Form 4 indicates routine executive compensation activity rather than an opportunistic trading pattern. The reporting person acquired 4,203 shares through settlement of RSUs/PSUs on 08/17/2025, increasing beneficial ownership to 132,142 shares, then sold 2,649 shares on 08/18/2025 at $13.187 to satisfy tax withholding. These transactions are consistent with automated sell-to-cover tax actions described in the filing and reflect scheduled vesting schedules established in 2022. No discretionary large-scale divestiture or new open-market purchases are reported.
TL;DR Transactions appear procedural for compensation settlement and tax compliance, not a governance red flag.
The filing documents settlement of RSUs/PSUs and an immediate sell-to-cover to satisfy statutory tax obligations. The disclosure clearly states the sale was to cover withholding and "does not represent a discretionary transaction." Vesting schedules are specified and originate from 2022 grant commencement dates. From a governance perspective, the filing contains required transparency and shows adherence to routine equity award mechanics and reporting obligations.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 2,649 | $13.187 | $35K |
| Exercise | Restricted Stock Unit | 1,773 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 2,430 | $0.00 | -- |
| Exercise | Common Stock | 4,203 | $0.00 | -- |
Footnotes (1)
- Each restricted stock unit ("RSU") and performance stock unit ("PSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs and PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on August 17, 2022, subject to continued service through each vesting date. 1/12th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on November 17, 2022, subject to continued service through each vesting date.
